Zhimeng Biopharma EN | 简体
Zhimeng Biopharma
  • Home
  • About Us
  • People
    • Leadership Team
    • Management Team
    • Scientific Advisors
  • Pipeline
  • News
  • Investors
  • Join Us
  • Contact

People

Scientific Advisors

Fabien Zoulim, M.D., Ph.D.

Fabien Zoulim, M.D., Ph.D.

Pei-Jer Chen, MD, Ph.D.

Pei-Jer Chen, MD, Ph.D.

Junqi Niu, M.D., Ph.D.

Junqi Niu, M.D., Ph.D.

Kewei Wang, M.D., Ph.D.

Kewei Wang, M.D., Ph.D.

Get in touch

Contact Us About Us Leadership Team Management Team Scientific Advisors
Quick Links
  • About Us
  • Contact Us
  • Join Us
  • Pipeline
  • Leadership Team
  • Management Team
  • Scientific Advisors
Recent News
  • Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R
  • Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.
  • Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019
  • Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

© 2020 Zhimeng Biopharma. All Rights Reserved. 备案号:沪ICP备18045542号-1 | 沪公网安备 31011502011190号

© 2020 Zhimeng Biopharma. All Rights Reserved.